They probably didn't want to step on the news of the ACTIV-5 topline results. “We look forward to the announcement of the topline data from a second phase 2/3 study of lenzilumab in COVID-19, the ACTIV-5/BET-B study conducted by the National Institutes of Health, in late Q1 or early Q2." So the topline results may be announced earlier than expected.
Of course, that would lead to further news announcing the submission of our amended EUA, including the ACTIV-5 trial results.